Acadian Asset Management LLC Increases Position in Enanta Pharmaceuticals, Inc. $ENTA

Acadian Asset Management LLC raised its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 2.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 867,037 shares of the biotechnology company’s stock after buying an additional 17,613 shares during the period. Acadian Asset Management LLC owned approximately 4.06% of Enanta Pharmaceuticals worth $4,782,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. American Century Companies Inc. boosted its position in Enanta Pharmaceuticals by 8.2% during the first quarter. American Century Companies Inc. now owns 40,004 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 3,042 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Enanta Pharmaceuticals by 3.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 159,801 shares of the biotechnology company’s stock valued at $882,000 after buying an additional 4,974 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Enanta Pharmaceuticals by 23.7% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 30,465 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 5,829 shares in the last quarter. US Bancorp DE purchased a new stake in Enanta Pharmaceuticals in the 1st quarter valued at approximately $36,000. Finally, Goldman Sachs Group Inc. lifted its stake in Enanta Pharmaceuticals by 5.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after buying an additional 6,549 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ENTA has been the topic of a number of recent research reports. Westpark Capital initiated coverage on Enanta Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a “buy” rating and a $24.00 target price on the stock. JMP Securities upped their target price on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 12th. Wall Street Zen raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, June 22nd. Finally, HC Wainwright initiated coverage on Enanta Pharmaceuticals in a research note on Monday, July 28th. They issued a “buy” rating and a $20.00 target price on the stock. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $22.25.

Enanta Pharmaceuticals Stock Down 4.4%

ENTA stock opened at $8.28 on Friday. The company has a market cap of $177.03 million, a price-to-earnings ratio of -1.92 and a beta of 0.84. The business has a fifty day simple moving average of $7.86 and a 200-day simple moving average of $6.79. Enanta Pharmaceuticals, Inc. has a 52 week low of $4.09 and a 52 week high of $13.37.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The business had revenue of $18.31 million during the quarter, compared to the consensus estimate of $16.21 million. As a group, analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.